SCHEMBL21999683

SCHEMBL21999683

O=C(O)c1ccc(-c2ccccc2)cc1NS(=O)(=O)c1cc(Cl)cc2c1OCC2

nearest known ligand 0.63

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ACLY P53396 20/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21999571 0.78 ACLY (1.00) ACLY
SCHEMBL22000144 0.77 ACLY (1.00) ACLY
SCHEMBL21931003 0.77 ACLY (1.00) ACLY
SCHEMBL21931067 0.76 ACLY (1.00) ACLY
SCHEMBL22000661 0.75 ACLY (0.82) ACLY
SCHEMBL9997431 0.75 PFKFB3 (0.52) ACLY
SCHEMBL21930807 0.74 ACLY (1.00) ACLY
SCHEMBL21999595 0.74 ACLY (0.82) ACLY
SCHEMBL21930839 0.73 ACLY (1.00) ACLY
SCHEMBL4960610 0.72 PKM (0.44) ACLY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200148634-A1 ACLY INHIBITORS AND USES THEREOF Nimbus Artemis, Inc. 2020-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200148634-A1 ACLY INHIBITORS AND USES THEREOF ACLY, ATP5ME, ATP5MG ACLY 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.